Clinical Scorecard: Role of Hemagglutination-Inhibition Antibodies in Influenza Protection Among Children Vaccinated with Inactivated and Live Attenuated Vaccines

At a Glance

Key Highlights

• HAI titers elicited by both trivalent live attenuated influenza vaccine (LAIV3) and inactivated influenza vaccine (IIV3) are associated with protection against influenza infection in children.
• Each log2 increase in postvaccination HAI titer against predominant circulating strains reduces influenza risk by approximately 30%–35%.
• HAI titers are a valid correlate of protection for both LAIV3 and IIV3 despite generally lower titers observed with LAIV3.

Guideline-Based Recommendations

Diagnosis

• Use RT-PCR confirmation for symptomatic influenza diagnosis in vaccinated children.

Management

• Administer either intranasal trivalent LAIV3 or intramuscular trivalent IIV3 for influenza vaccination in children aged 3–15 years.
• Provide a second vaccine dose 1 month after the first for children under 9 years without prior vaccination history.

Monitoring & Follow-up

• Measure postvaccination HAI titers to assess immune response and correlate with protection.
• Conduct symptom surveillance twice weekly during influenza season with nasal swab collection for RT-PCR testing when ≥2 symptoms are present.

Risks

• No specific vaccine-related risks detailed; both LAIV3 and IIV3 are considered safe and efficacious in the target population.

Patient & Prescribing Data

Children aged 3–15 years in community settings

Both LAIV3 and IIV3 effectively elicit protective HAI antibodies; LAIV3 may produce lower HAI titers but still confer protection when vaccine strains match circulating influenza subtypes.

Clinical Best Practices

• Use HAI titer ≥1:40 as a correlate of protection against influenza infection in children.
• Select vaccine strains that closely match circulating influenza virus subtypes to maximize protective efficacy.
• Implement cluster-randomized controlled trial designs in community settings to evaluate vaccine effectiveness and immune correlates.

References

• Hemagglutination-inhibition antibodies and protection for influenza elicited by inactivated and live attenuated vaccines in children